IRLAB A — IRLAB Therapeutics AB Share News
0.000.00%
Last trade - 00:00- SEK165.12m
- SEK155.10m
- SEK57.46m
Brief: Irlab Therapeutics Gets Approval From Swedish Medical Products Agency
Brief: Irlab Q4 Operating Loss Widens To SEK 35.7 Mln
Brief: IRLAB Granted End-Of-Phase 2 Meeting With FDA For Mesdopetam Program
Brief: IRLAB Extends CEO Appointment
Brief: IRLAB Therapeutics Increases Liquidity With Loan Facility Of Up To SEK 55 Mln
Brief: IRLAB Receives $2 Mln Grant From Michael J. Fox Foundation For Apathy Treatment
Brief: IRLAB Granted Patent For Drug Candidate Pirepemat
Brief: IRLAB Q3 Adj, EPS at SEK -0.74
Brief: Irlab Signs With Regulatory Consultants Ahead Of FDA Mesdopetam Meeting
Brief: IRLAB Therapeutics April-June Operating Loss Widens To SEK 44.9 Mln
Brief: IRLAB Secures Full Ownership Of Mesdopetam Project, Continues Product Development
Brief: Irlab’S Phase IIb Study With Pirepemat Passes Dsmb Safety Review
Brief: IRLAB Activates All Study Sites In Phase IIb Study Of Pirepemat
Brief: Irlab Q1 Operating Loss SEK 59.5 Mln
Brief: Irlab Therapeutics Q4 Oper Loss Widens To SEK 33.1 Mln
Brief: IRLAB Changes CEO, Appoints New Chairman
Brief: IRLAB: Top-Line Results From Phase IIb Trial Of Mesdopetam In Parkinson's Disease
Brief: IRLAB Nominates IRL1117 As Drug Candidate To Develop Treatment For Parkinson's
Brief: IRLAB Updates On Swedish ECA Investigation